Grade 3-4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study.
Nadia GuezourGhassen SoussiSolenn BrosseauBaptiste AbbarCharles NaltetCharles VauchierNicolas PotéLorry HachonCéline NamourAntoine KhalilJean TrédanielGérard ZalcmanValérie GounantPublished in: Cancers (2022)
Our real-life study confirms that high-grade irAEs predict longer OS in advanced NSCLC.